• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

PFE offered AGN $160B in 2015...now ABBV is paying $63?

One must remember that AGN did get $40bb for its generic business, but even taking that into account the current bid is about half the value of the PFE bid. BS was brought in to sell AGN to PFE and it all blew up. He spent WAY over $100bb buying and merging companies that are now worth a fraction of that amount. He destroyed positive corporate cultures and thousands of careers at multiple companies. But he did become the most prolific posting CEO on twitter. Great job, BS....

$10bb of the $40bb was in Teva stock...Allergan lost a ton of that $10bb value.